Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.

Haematologica - 1 Oct 2004

Yavarian Majid, Karimi Mehran, Bakker Egbert, Harteveld Cornelis L, Giordano Piero C

Abstract excerpt

BACKGROUND AND OBJECTIVES: Hydroxyurea (HU) is known to increase gamma-globin chain expression in postnatal life. The efficacy of HU treatment in thalassemia patients is still unclear. The aim of this study was to monitor treatment of a large cohort of patients with beta-thalassemia major in order to establish the response to HU and the associated elements. DESIGN AND METHODS: HU therapy was started in 133...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta-Thalassemia
Share to Blood Transfusion
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fetal Hemoglobin

Share to Genetic Heterogeneity

Share to Globins

Share to Hydroxyurea

Share to Splenectomy

Source

Identifiers

PMID: 15477200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.PMID 15477200Read ↗

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.Semantic proximity Read ↗

The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.Semantic proximity Read ↗

Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.Semantic proximity Read ↗

Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphismSemantic proximity Read ↗

Response to hydroxyurea therapy in beta-thalassemia.Semantic proximity Read ↗

Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.Semantic proximity Read ↗

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?Semantic proximity Read ↗

Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the XmnI Polymorphism.Semantic proximity Read ↗

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.Semantic proximity Read ↗

Do alpha deletions influence hydroxyurea response in thalassemia intermedia?Semantic proximity Read ↗

A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.Semantic proximity Read ↗

Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyureaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.